Figure 1

Flow chart illustrating the study progress from initial enrollment, through randomization, to primary endpoint assessment.

Assessed for eligibility (n=126 )
- Excluded (n=26 )
  - Not meeting inclusion criteria (n=23 )
    - Bleeding tendency (n=8), Malignancy (n=5), prior PPI usage (n=10)
  - Declined to participate (n=3 )

Randomized (n=100 )

Allocation
- Allocated to iv ESO (n=50 )
  - Received allocated intervention (n=50 )
- Allocated to oral LAN (n=50 )
  - Received allocated intervention (n=50 )

Follow-Up
- Lost to follow-up (n=0 )
- Discontinued intervention (n=0 )

Analysis
- Analysed (n=50 )
  - Excluded from analysis (n=0 )
  - Re-bleeding (n=2)
  - Hemostasis (n=48)
- Analysed (n=50 )
  - Excluded from analysis (n=0 )
  - Re-bleeding (n=2)
  - Hemostasis (n=48)